Patient-derived xenograft (PDX) platform comprises 89 metastatic melanoma tumors
Platform includes several pre-vemurafenib and vemurafenib-resistant PDXs
Duplication of the BRAFV600E kinase domain is identified as a resistance mechanism
Pan-RAF dimerization inhibitor LY3009120 eliminates melanoma cells with this duplication